Germany
· Delayed Price · Currency is EUR Royalty Pharma Statistics
Total Valuation
Royalty Pharma has a market cap or net worth of EUR 12.48 billion. The enterprise value is 21.37 billion.
| Market Cap | 12.48B |
| Enterprise Value | 21.37B |
Important Dates
The next estimated earnings date is Thursday, May 8, 2025.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | Feb 21, 2025 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -1.46% |
| Shares Change (QoQ) | -0.63% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 378.30M |
Valuation Ratios
The trailing PE ratio is 15.04.
| PE Ratio | 15.04 |
| Forward PE | n/a |
| PS Ratio | 5.71 |
| PB Ratio | 1.25 |
| P/TBV Ratio | 1.86 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 4.67 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 25.75 |
| EV / Sales | 10.64 |
| EV / EBITDA | n/a |
| EV / EBIT | 18.23 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.44, with a Debt / Equity ratio of 0.74.
| Current Ratio | 1.44 |
| Quick Ratio | 1.43 |
| Debt / Equity | 0.74 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 5.73 |
Financial Efficiency
Return on equity (ROE) is 13.03% and return on invested capital (ROIC) is 4.73%.
| Return on Equity (ROE) | 13.03% |
| Return on Assets (ROA) | 4.67% |
| Return on Invested Capital (ROIC) | 4.73% |
| Return on Capital Employed (ROCE) | 7.62% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +9.31% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +9.31% |
| 50-Day Moving Average | 29.85 |
| 200-Day Moving Average | 26.94 |
| Relative Strength Index (RSI) | 45.03 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 4.55 |
Income Statement
In the last 12 months, Royalty Pharma had revenue of EUR 2.19 billion and earned 829.69 million in profits. Earnings per share was 1.85.
| Revenue | 2.19B |
| Gross Profit | 1.48B |
| Operating Income | 1.25B |
| Pretax Income | 1.29B |
| Net Income | 829.69M |
| EBITDA | n/a |
| EBIT | 1.25B |
| Earnings Per Share (EPS) | 1.85 |
Balance Sheet
The company has 953.56 million in cash and 7.35 billion in debt, giving a net cash position of -6.40 billion.
| Cash & Cash Equivalents | 953.56M |
| Total Debt | 7.35B |
| Net Cash | -6.40B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 9.99B |
| Book Value Per Share | 15.04 |
| Working Capital | 529.82M |
Cash Flow
| Operating Cash Flow | 2.67B |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 67.64%, with operating and profit margins of 57.10% and 37.95%.
| Gross Margin | 67.64% |
| Operating Margin | 57.10% |
| Pretax Margin | 58.79% |
| Profit Margin | 37.95% |
| EBITDA Margin | n/a |
| EBIT Margin | 57.10% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.79, which amounts to a dividend yield of 2.79%.
| Dividend Per Share | 0.79 |
| Dividend Yield | 2.79% |
| Dividend Growth (YoY) | 6.04% |
| Years of Dividend Growth | 5 |
| Payout Ratio | 43.83% |
| Buyback Yield | 1.46% |
| Shareholder Yield | 4.25% |
| Earnings Yield | 6.65% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Royalty Pharma has an Altman Z-Score of 1.56. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.56 |
| Piotroski F-Score | n/a |